614-864-4919 info@sermonixpharma.com
  • LinkedIn
  • Facebook
  • Twitter
  • RSS
  • LinkedIn
  • Facebook
  • Twitter
  • RSS
Sermonix Pharmaceuticals
  • About
    • Company Overview
    • Management Team
    • Board of Directors
    • Oncology Steering Committee
    • Partners & Collaborations
  • Breast Cancer
  • Pipeline
    • Lasofoxifene
  • ELAINE Studies
    • The ELAINE-1 Study
    • The ELAINE-2 Study
    • Who is Elaine?
    • About Expanded Access
    • EQUALS
  • News & Media
    • News
    • Media
  • Posters & Presentations
  • Contact
Select Page

Sermonix Pharmaceuticals and Quantum Leap Healthcare Announce New Study Arm to Evaluate Lasofoxifene in Ongoing I-SPY 2 Clinical Trial

by Sermonix Pharmaceuticals | Feb 13, 2023 | News

Posters were presented Dec. 9 at the San Antonio Breast Cancer Symposium (SABCS) One abstract addressed patients who participated in the randomized Phase 2 ELAINE 1 study that assessed investigational lasofoxifene versus fulvestrant Second abstract addressed patients...

Sermonix to Present Poster Comparing Lasofoxifene and Fulvestrant Effect on Vaginal Health at International Society for the Study of Women’s Sexual Health Annual Meeting 2023

by Sermonix Pharmaceuticals | Feb 8, 2023 | News

Posters were presented Dec. 9 at the San Antonio Breast Cancer Symposium (SABCS) One abstract addressed patients who participated in the randomized Phase 2 ELAINE 1 study that assessed investigational lasofoxifene versus fulvestrant Second abstract addressed patients...

Recent Posts

  • Sermonix Pharmaceuticals to Host Oral Presentation on Vaginal and Sexual Health at RISE UP for Breast Cancer Conference
  • Sermonix Pharmaceuticals Completes Enrollment of Phase 2 I-SPY 2 Arm Evaluating Lasofoxifene in Neoadjuvant Breast Cancer Setting
  • Sermonix Pharmaceuticals Receives U.S. Patent for Lasofoxifene as Method for Treating Aromatase-Resistant ER+ Breast Cancer in the Absence of ESR1 Mutations
  • Sermonix Pharmaceuticals Announces Breast Cancer Research Publication of Paper Examining Lasofoxifene’s Preclinical Effects on Aromatase Inhibitor Resistant Non-ESR1 Mutated Breast Cancer
  • Sermonix Pharmaceuticals Announces Chinese Approval of Investigational New Drug Application for Lasofoxifene

Recent Comments

    Archives

    • October 2024
    • August 2024
    • July 2024
    • June 2024
    • April 2024
    • February 2024
    • January 2024
    • December 2023
    • November 2023
    • October 2023
    • September 2023
    • June 2023
    • May 2023
    • March 2023
    • February 2023
    • December 2022
    • November 2022
    • September 2022
    • August 2022
    • June 2022
    • April 2022
    • February 2022
    • December 2021
    • November 2021
    • June 2021
    • May 2021
    • April 2021
    • January 2021
    • December 2020
    • October 2020
    • September 2020
    • July 2020
    • June 2020
    • December 2019
    • September 2019
    • June 2019
    • May 2019
    • April 2019
    • March 2019

    Categories

    • News

    Meta

    • Log in
    • Entries feed
    • Comments feed
    • WordPress.org

    © Sermonix Pharmaceuticals